SAREPTA THERAPEUTICS, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
SAREPTA THERAPEUTICS, INC. (SRPT) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$35.67 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-05-03
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2018-03-31 was -$35.67M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$31.06M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$57.90M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$85.15M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$232.00M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$245.82M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$149.47M.
- SAREPTA THERAPEUTICS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$128.54M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 404 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$35.67M 10-Q · filed 2018-05-03 | -$66.73M derived: sum of 2 quarters · filed 2018-05-03 | -$124.63M derived: sum of 3 quarters · filed 2018-05-03 | -$209.78M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-12-31 | -$31.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$88.96M derived: sum of 2 quarters · filed 2018-03-01 | -$174.11M derived: sum of 3 quarters · filed 2018-03-01 | -$232.00M 10-K · filed 2018-03-01 | |
| 2017-09-30 | -$57.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$143.05M derived: sum of 2 quarters · filed 2017-11-01 | -$200.94M 10-Q · filed 2017-11-01 | -$282.17M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-06-30 | -$85.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$143.03M 10-Q · filed 2017-08-03 | -$224.27M derived: sum of 3 quarters · filed 2018-05-03 | -$284.88M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2017-03-31 | -$57.89M 10-Q · filed 2018-05-03 | -$139.12M derived: sum of 2 quarters · filed 2018-05-03 | -$199.74M derived: sum of 3 quarters · filed 2018-05-03 | -$243.02M derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | -$81.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$141.85M derived: sum of 2 quarters · filed 2018-03-01 | -$185.13M derived: sum of 3 quarters · filed 2018-03-01 | -$245.82M 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$60.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$103.90M derived: sum of 2 quarters · filed 2017-11-01 | -$164.59M 10-Q · filed 2017-11-01 | -$195.86M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | -$43.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$103.97M 10-Q · filed 2017-08-03 | -$135.24M derived: sum of 3 quarters · filed 2018-03-01 | -$181.56M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | -$60.69M 10-Q · filed 2017-05-04 | -$91.96M derived: sum of 2 quarters · filed 2018-03-01 | -$138.27M derived: sum of 3 quarters · filed 2018-03-01 | -$166.81M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | -$31.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$77.59M derived: sum of 2 quarters · filed 2018-03-01 | -$106.12M derived: sum of 3 quarters · filed 2018-03-01 | -$149.47M 10-K · filed 2018-03-01 | |
| 2015-09-30 | -$46.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$74.84M derived: sum of 2 quarters · filed 2016-11-07 | -$118.19M 10-Q · filed 2016-11-07 | -$143.64M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | -$28.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$71.88M 10-Q · filed 2016-08-09 | -$97.33M derived: sum of 3 quarters · filed 2017-02-28 | -$132.65M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | -$43.35M 10-Q · filed 2016-05-05 | -$68.80M derived: sum of 2 quarters · filed 2017-02-28 | -$104.12M derived: sum of 3 quarters · filed 2017-02-28 | -$143.62M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | -$25.45M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$60.77M derived: sum of 2 quarters · filed 2017-02-28 | -$100.27M derived: sum of 3 quarters · filed 2017-02-28 | -$128.54M 10-K · filed 2017-02-28 | |
| 2014-09-30 | -$35.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$74.83M derived: sum of 2 quarters · filed 2015-11-05 | -$103.09M 10-Q · filed 2015-11-05 | -$120.91M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | -$39.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$67.77M 10-Q · filed 2015-08-06 | -$85.59M derived: sum of 3 quarters · filed 2016-02-25 | -$105.47M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | -$28.27M 10-Q · filed 2015-05-07 | -$46.09M derived: sum of 2 quarters · filed 2016-02-25 | -$65.97M derived: sum of 3 quarters · filed 2016-02-25 | -$77.97M derived: sum of 4 quarters · filed 2016-02-25 | -$352.87M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$17.82M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$37.70M derived: sum of 2 quarters · filed 2016-02-25 | -$49.70M derived: sum of 3 quarters · filed 2016-02-25 | -$64.69M 10-K · filed 2016-02-25 | |
| 2013-09-30 | -$19.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$31.88M derived: sum of 2 quarters · filed 2014-11-06 | -$46.87M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | -$12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$27.00M 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | -$14.99M 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | -$29.69M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |